View in Other Languages

Regeneus Ltd

ASX:RGS ISIN:AU000000RGS6

Regeneus Ltd ASX:RGSRegeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza(TM) and Sygenus. Visit www.regeneus.com.au for more information.

       

News

Regeneus Ltd (ASX:RGS) Research Collaboration with the Kolling Institute's Raymond Purves Bone and Joint Research Laboratory

🕔7/28/2021 6:30:48 PM 2041

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce a research collaboration with Professor Christopher Little and the Raymond Purves Bone and Joint Research Laboratory at the Kolling Institute at Royal North Shore Hospital, Australia.

Read Full Article

Regeneus Ltd (ASX:RGS) Receives Milestone Payment from Kyocera

🕔8/28/2020 10:06:35 AM 2709

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce that is has received a payment of 100M JPY (~A$1.3M) from Kyocera Corporation (Kyocera, TYO:6971)

Read Full Article

Regeneus Ltd (ASX:RGS) To present at FNN Virtual Investor Event

🕔8/25/2020 11:39:09 AM 1973

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced that its CEO Leo Lee, will present at the Finance News Network (FNN) CEO Showcase virtual event on Tuesday 25 August 2020 at 12:55pm (AEST). The event is primarily attended by Australian-based retail investors and advisors.

Read Full Article

Regeneus Ltd (ASX:RGS) US Patent for Sygenus

🕔8/19/2020 9:26:38 AM 1913

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced that the U.S Patent and Trademark Office (USPTO) has issued a notice of allowance for issuance of a new key patent for the Company's Secretome technology platform, Sygenus, in the U.S.

Read Full Article

Regeneus Ltd (ASX:RGS) and Kyocera Sign Progenza OA Deal

🕔8/11/2020 9:51:25 AM 2051

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced that Kyocera Corporation (Kyocera, TYO:6971) has signed a licence agreement to develop and commercialise Progenza for Knee Osteoarthritis (Progenza OA) in Japan.

Read Full Article

Regeneus Ltd (ASX:RGS) Quarterly Report

🕔7/31/2020 4:04:34 PM 1959

During the quarter, Regeneus Ltd (ASX:RGS) received notification from Kyocera Corporation (TYO:6971) that its lead stem cell platform technology Progenza for the treatment of Knee Osteoarthritis (Progenza OA) had passed Kyocera's due diligence process.

Read Full Article

Regeneus Ltd (ASX:RGS) Progenza OA Kyocera Negotiations Update

🕔7/28/2020 9:34:41 AM 1842

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today provides an update on its negotiations with Kyocera Corporation (TYO:6971) for a licence agreement to develop and commercialise Progenza for Knee Osteoarthritis in Japan

Read Full Article

Regeneus Ltd (ASX:RGS) Featured in Morgans' 'Under The Microscope' Podcast series

🕔7/11/2020 9:00:15 AM 2496

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, was recently featured in the 'Under the Microscope' podcast series from Morgans.

Read Full Article

Regeneus Ltd (ASX:RGS) Director Resignation

🕔6/4/2020 10:53:55 AM 2179

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced that non-executive director Dr Glen Richards has resigned to allow him to focus on his other commitments.

Read Full Article

Regeneus Ltd (ASX:RGS) Kyocera completes Progenza Due Diligence

🕔5/18/2020 8:39:52 AM 2712

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced that it has received notification that Kyocera Corporation (TYO:6971) has completed its due diligence process on its lead stem cell platform technology Progenza for treatment of Knee Osteoarthritis (Progenza OA).

Read Full Article
###

166,414 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 138) (Last 30 Days: 585) (Since Published: 78716) 

Company Data

    Headquarters
  • 2 Paddington Street
    Paddington NSW 2021
    Australia
  • Telephone
  • +61-2-9499-8010 
  • Fax
  • +61-2-9499-8020 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.regeneus.com.au
  • E:
  • info@regeneus.com.au

Company Reports